All News

RheumNow Podcast square

Social Media Questions (7.29.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and rheumatologist cases from the past week on RheumNow.com. This podcast is brought to you by StillsNow.com - be sure to sign up for our monthly StillsNow email and Monthly StillsNow Podcast.

Read Article
Lungs ILD

Approach to ILD in Myositis Syndromes

d Jack Cush, MD

Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.

Read Article
Fever,temp,man,HA,thermometer

Rheumatic Causes for Fever of Unknown Origin

d Jack Cush, MD

Fever of unknown origin (FUO) represents a diagnostic challenge to many physicians and while cancer and infectious causes need to be excluded, rheumatic disorders are amongst the most common causes of FUO.

Read Article
blood, level, numbers, data, calculation

Best Labs for Still’s Disease

d Jack Cush, MD

There is no “test” (blood or other) that is solely diagnostic of Still’s disease, but labs can help make a diagnosis or manage disease, and affirm the safety of drugs in use. ​​​​​​​ 

Read Article
Best of

U.S. News & World Report’s 2022–23 Rheumatology Rankings

d Jack Cush, MD

The Johns Hopkins Hospital has repeated its top rank among US Rheumatology centers - ranking #1 for the 18th year in a row, according to U.S. News & World Report’s 2022–23 Best Hospitals list released yesterday.

Read Article
Get insights to difficult to treat rheumatoid arthritis #D2T from the experts👉 This report summarizes what we know and what we still need to know! https://t.co/Qdkcu0Z2sk https://t.co/FW5rvSK1vi

Links:

ARD & RMD Open ARD_BMJ ( View Tweet)
Best Labs for Still’s Disease There is no “test” (blood or other) that is solely diagnostic of Still’s disease, but labs can help make a diagnosis or manage disease, and affirm the safety of drugs in use. What tests should you be ordering? https://t.co/24QSfEEVwG https://t.co/bdrvSBd652

Links:

Dr. John Cush RheumNow ( View Tweet)
The Johns Hopkins Hospital has repeated its top rank among US Rheumatology centers - ranking #1 for the 18th year in a row, according to U.S. News & World Report’s 2022–23 Best Hospitals list. https://t.co/dC5vVEhCrC https://t.co/skXbg1fAve

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 63 Thalassemia pts (50 transfusion dep) w/ 22% α-, 73% β-, 5% α- & β-thal. 23 had inflammatory rheumatic Dz (IRD: RA 9, gout 6, SLE 3, SpA 2). ANA+ in 10% w/o IRD & Transfusion Dep had more + tests for direct Coombs & ANA https://t.co/QW6ecv98F1 https://t.co/GO3xC86hLc

Links:

Dr. John Cush RheumNow ( View Tweet)
TREAT EARLIER Study - Is MTX Intevention in Pre-Clinical RA Warranted? https://t.co/rGcm1DSwJk https://t.co/paBrJVMXdP

Links:

Dr. John Cush RheumNow ( View Tweet)
Belimumab (Benlysta) has been FDA approved for use in pediatric patients with active lupus nephritis who are receiving standard lupus therapy. The approval in kids is for the IV formulation only; SC belimumab is for SLE and LN in adults https://t.co/LCUFDpZM6j https://t.co/R2kA2DbxKy

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of cardiovascular effects of Colchicine: 21 RCTs (15,569 pts shows colchicine was superior to placebo reducing CV events; with lower risk recurrent pericarditis (RR 0.50), MACE (RR 0.67), & AFib recurrence (RR 0.68) https://t.co/oQEF7dmkH8 https://t.co/P7IKeZpcUB

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center, retrospective chart study shows that in 168 PsA patients, 26% were assessed within 6wks of referral. Median wait time = 78.5 d. The most common cause of delay was the lack of available spots in the PsA clinic. https://t.co/FDfFgxHhLD https://t.co/CYoT1PBp8l

Links:

Dr. John Cush RheumNow ( View Tweet)
No Risk of RA w/ coffee consumption -- Swedish EIRA study, included 2184 early RA pts. High Coffee (>6 cups/day) was assoc w/ increased RA risk (OR 1.50;1.20–1.88) that was lost after adjusting for smoking (OR 1.14;0.89–1.45). https://t.co/3SIeHD4fII https://t.co/NqkjmuzSaV

Links:

Dr. John Cush RheumNow ( View Tweet)
Nintedinib’s Durable Efficacy in Systemic Sclerosis Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said. https://t.co/7rUuB6RRow https://t.co/MqBjOj1myW

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 13 trials of corticosteroids (CS) in hand #OA shows no significant effect of intra-articular CS for CMC1 OA (pain or function); but medium effect of oral CS on pain & stiffness & functional improvement at 4-6 weeks. https://t.co/u30bPuQOOr https://t.co/4Z1ZpiOcvX

Links:

Dr. John Cush RheumNow ( View Tweet)
EMA in Europe has approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who are DMARD-IR or biologic-IR. Based on 3 phase III trials. https://t.co/BjvUm0wPNk https://t.co/IVisAgD1wZ

Links:

Dr. John Cush RheumNow ( View Tweet)
BSRBR mandates LFTs q3 mos if on MTX. 1011 RA pts during the pandemic had median of 5 blood tests & median interval of 57 days. 61% pts had 1 prolonged interval (99-150d) & 24% had multiple. Cytopenia & ^LFTs were not increased by interval length https://t.co/VqY4qIMvOS https://t.co/HcTcmFBuvq

Links:

Dr. John Cush RheumNow ( View Tweet)
210 consecutive #RA pts starting #MTX looked at effect of autoantibodies on drug response. DAS28-CRP low dz activity at 6 mos was significantly lower with SSA+ (56% v 76%, P=0.03) - which was more significant than CCP+ or RF+ https://t.co/DoEtldBXi4 Figures https://t.co/yIECjLiEwl

Links:

Dr. John Cush RheumNow ( View Tweet)
Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders. https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz

Links:

Dr. John Cush RheumNow ( View Tweet)
×